vs
Side-by-side financial comparison of ALKAMI TECHNOLOGY, INC. (ALKT) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $126.1M, roughly 1.4× ALKAMI TECHNOLOGY, INC.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -7.9%, a 9.5% gap on every dollar of revenue. On growth, ALKAMI TECHNOLOGY, INC. posted the faster year-over-year revenue change (28.9% vs 5.0%). Over the past eight quarters, ALKAMI TECHNOLOGY, INC.'s revenue compounded faster (23.9% CAGR vs -0.2%).
Alkami Technology, Inc. delivers cloud-native digital banking platforms and supporting solutions for US financial institutions. Its offerings include online and mobile banking interfaces, payment processing tools, data analytics modules, and customer engagement functionalities, primarily serving community banks and credit unions to enhance their customers' digital banking experiences.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
ALKT vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $126.1M | $177.4M |
| Net Profit | $-10.0M | $2.9M |
| Gross Margin | 58.6% | — |
| Operating Margin | 36.9% | 3.9% |
| Net Margin | -7.9% | 1.6% |
| Revenue YoY | 28.9% | 5.0% |
| Net Profit YoY | -27.5% | — |
| EPS (diluted) | — | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $126.1M | $177.4M | ||
| Q4 25 | $120.8M | $196.9M | ||
| Q3 25 | $113.0M | $179.5M | ||
| Q2 25 | $112.1M | $181.1M | ||
| Q1 25 | $97.8M | $168.9M | ||
| Q4 24 | $89.7M | $187.3M | ||
| Q3 24 | $85.9M | $168.6M | ||
| Q2 24 | $82.2M | $178.0M |
| Q1 26 | $-10.0M | $2.9M | ||
| Q4 25 | — | — | ||
| Q3 25 | $-14.8M | $5.4M | ||
| Q2 25 | $-13.6M | $-4.8M | ||
| Q1 25 | — | $4.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-9.4M | $-143.5M | ||
| Q2 24 | $-12.3M | $18.9M |
| Q1 26 | 58.6% | — | ||
| Q4 25 | 57.2% | 79.5% | ||
| Q3 25 | 56.8% | 80.9% | ||
| Q2 25 | 58.6% | 77.4% | ||
| Q1 25 | 59.0% | 79.7% | ||
| Q4 24 | 59.3% | 78.7% | ||
| Q3 24 | 58.9% | 76.9% | ||
| Q2 24 | 59.4% | 75.1% |
| Q1 26 | 36.9% | 3.9% | ||
| Q4 25 | -7.9% | 1.2% | ||
| Q3 25 | -11.4% | 3.5% | ||
| Q2 25 | -14.2% | 4.7% | ||
| Q1 25 | -15.7% | 1.2% | ||
| Q4 24 | -9.6% | 13.2% | ||
| Q3 24 | -12.1% | -82.8% | ||
| Q2 24 | -16.1% | 15.9% |
| Q1 26 | -7.9% | 1.6% | ||
| Q4 25 | — | — | ||
| Q3 25 | -13.1% | 3.0% | ||
| Q2 25 | -12.1% | -2.7% | ||
| Q1 25 | — | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | -11.0% | -85.1% | ||
| Q2 24 | -15.0% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-0.11 | $0.05 | ||
| Q3 25 | $-0.14 | $0.12 | ||
| Q2 25 | $-0.13 | $-0.11 | ||
| Q1 25 | $-0.08 | $0.10 | ||
| Q4 24 | $-0.07 | $0.38 | ||
| Q3 24 | $-0.09 | $-3.11 | ||
| Q2 24 | $-0.13 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.4M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $370.7M | $653.9M |
| Total Assets | $829.3M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $40.4M | $144.3M | ||
| Q4 25 | $63.5M | $238.4M | ||
| Q3 25 | $57.3M | $246.3M | ||
| Q2 25 | $52.4M | $445.9M | ||
| Q1 25 | $61.7M | $493.6M | ||
| Q4 24 | $94.4M | $484.6M | ||
| Q3 24 | $81.0M | $453.8M | ||
| Q2 24 | $61.4M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $370.7M | $653.9M | ||
| Q4 25 | $362.0M | $693.1M | ||
| Q3 25 | $350.1M | $727.2M | ||
| Q2 25 | $344.0M | $757.8M | ||
| Q1 25 | $334.0M | $798.5M | ||
| Q4 24 | $357.0M | $778.3M | ||
| Q3 24 | $338.5M | $749.6M | ||
| Q2 24 | $327.2M | $879.3M |
| Q1 26 | $829.3M | $1.2B | ||
| Q4 25 | $847.2M | $1.3B | ||
| Q3 25 | $835.2M | $1.3B | ||
| Q2 25 | $840.4M | $1.5B | ||
| Q1 25 | $837.2M | $1.6B | ||
| Q4 24 | $437.3M | $1.6B | ||
| Q3 24 | $422.2M | $1.5B | ||
| Q2 24 | $403.9M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.8M | — |
| Free Cash FlowOCF − Capex | $-7.4M | — |
| FCF MarginFCF / Revenue | -5.8% | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $40.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $-4.8M | — | ||
| Q4 25 | $16.6M | $43.7M | ||
| Q3 25 | $30.8M | $60.8M | ||
| Q2 25 | $1.2M | $12.0M | ||
| Q1 25 | $-5.7M | $35.5M | ||
| Q4 24 | $6.1M | $33.1M | ||
| Q3 24 | $11.0M | $53.9M | ||
| Q2 24 | $548.0K | $53.2M |
| Q1 26 | $-7.4M | — | ||
| Q4 25 | $16.2M | $43.5M | ||
| Q3 25 | $30.5M | $57.0M | ||
| Q2 25 | $760.0K | $9.3M | ||
| Q1 25 | $-6.1M | $26.9M | ||
| Q4 24 | $6.0M | $31.0M | ||
| Q3 24 | $10.7M | $49.8M | ||
| Q2 24 | $123.0K | $51.6M |
| Q1 26 | -5.8% | — | ||
| Q4 25 | 13.4% | 22.1% | ||
| Q3 25 | 27.0% | 31.7% | ||
| Q2 25 | 0.7% | 5.1% | ||
| Q1 25 | -6.3% | 15.9% | ||
| Q4 24 | 6.6% | 16.6% | ||
| Q3 24 | 12.4% | 29.6% | ||
| Q2 24 | 0.1% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.3% | 0.1% | ||
| Q3 25 | 0.2% | 2.2% | ||
| Q2 25 | 0.4% | 1.5% | ||
| Q1 25 | 0.5% | 5.1% | ||
| Q4 24 | 0.2% | 1.1% | ||
| Q3 24 | 0.4% | 2.4% | ||
| Q2 24 | 0.5% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALKT
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
